P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY‐DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH‐RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG‐HD7 TRIAL | Zendy

Mai E. K. | Zendy; Bertsch U. | Zendy; Fenk R. | Zendy; Tichy D. | Zendy; Besemer B. | Zendy; Dürig J. | Zendy; Schroers R. | Zendy; Metzler I. | Zendy; Hänel M. | Zendy; Mann C. | Zendy; Asemissen A. M. | Zendy; Heilmeier B. | Zendy; Nievergall E. | Zendy; Huhn S. | Zendy; Kriegsmann K. | Zendy; Weinhold N. | Zendy; Luntz S. | Zendy; Holderrried T. A. W. | Zendy; TrautmannGrill K. | Zendy; Gezer D. | Zendy; KlaiberHakimi M. | Zendy; Müller M. | Zendy; Khandanpour C. | Zendy; Knauf W. | Zendy; Scheid C. | Zendy; Munder M. | Zendy; Geer T. | Zendy; Riesenberg H. | Zendy; Thomalla J. | Zendy; Hoffmann M. | Zendy; Raab M. S. | Zendy; Salwender H. J. | Zendy; Weisel K. C. | Zendy; Goldschmidt H. | Zendy

Open Access

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY‐DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH‐RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG‐HD7 TRIAL

Author(s) -

Mai E. K.,

Bertsch U.,

Fenk R.,

Tichy D.,

Besemer B.,

Dürig J.,

Schroers R.,

Metzler I.,

Hänel M.,

Mann C.,

Asemissen A. M.,

Heilmeier B.,

Nievergall E.,

Huhn S.,

Kriegsmann K.,

Weinhold N.,

Luntz S.,

Holderrried T. A. W.,

TrautmannGrill K.,

Gezer D.,

KlaiberHakimi M.,

Müller M.,

Khandanpour C.,

Knauf W.,

Scheid C.,

Munder M.,

Geer T.,

Riesenberg H.,

Thomalla J.,

Hoffmann M.,

Raab M. S.,

Salwender H. J.,

Weisel K. C.,

Goldschmidt H.

Publication year - 2022

Publication title -

hemasphere

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.677

H-Index - 11

ISSN - 2572-9241

DOI - 10.1097/01.hs9.0000846588.94000.04

Subject(s) - lenalidomide , bortezomib , medicine , multiple myeloma , oncology , minimal residual disease , dexamethasone , induction therapy , clinical endpoint , gastroenterology , surgery , randomized controlled trial , chemotherapy , leukemia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore